Prenetics Global (NASDAQ:PRE) (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that develops and delivers health insights through its proprietary technology platforms. Founded in 2014 and headquartered in Hong Kong, Prenetics combines genomics, data analytics and telehealth to offer personalized health solutions spanning preventive care, sports performance and pharmaceutical development. The company’s business model integrates laboratory services with digital reporting tools, enabling clients to access actionable information about their genetic predispositions, nutritional needs and disease risks.
The company’s core products include at-home saliva and blood sample collection kits for genetic and diagnostic testing, complemented by an online portal and mobile app that provide users with real-time results, lifestyle recommendations and expert consultations. Prenetics’ services cover a broad spectrum of tests such as whole-genome sequencing, pharmacogenomics, microbiome analysis and COVID-19 screening. In addition, the firm offers specialized testing packages for elite athletes, corporate wellness programs and fertility clinics, tailoring test panels to the unique requirements of each segment.
Prenetics has established an international footprint across Asia, Europe, the Middle East and North America, operating clinical laboratories in Hong Kong, London and Los Angeles. The company partners with healthcare providers, research institutions and sports organizations to expand its distribution network and accelerate the adoption of precision medicine. Through strategic collaborations with pharmaceutical companies, Prenetics also supports drug development efforts by providing companion diagnostics and real-world evidence derived from its genomic database.
Led by co-founder and Chief Executive Officer Manny Miranda, Prenetics’ leadership team brings together expertise in biotechnology, software engineering and regulatory affairs. The company’s governance framework emphasizes quality management and compliance with international standards, including ISO accreditation for laboratory operations. By combining scientific innovation with scalable digital infrastructure, Prenetics aims to drive down the cost of genetic testing and empower individuals to make informed health decisions.
